Kintor PharmaceuticalKNTPF 26 Net Debt Paydown Yield % is 11.61% as of Jul. 08, 2026. GuruFocus rates KNTPF with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 1,157 Biotechnology companies, Kintor Pharmaceutical ranks better than 92.48% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Kintor Pharmaceutical's Net Debt Paydown Yield % was 11.61%.
Kintor Pharmaceutical (OTCPK:KNTPF) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Kintor Pharmaceutical Net Debt Paydown Yield % Related Terms
Kintor Pharmaceutical Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Kintor Pharmaceutical's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical Net Debt Paydown Yield % Chart
KNTPF vs VRTX, REGN, ALNY: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Kintor Pharmaceutical's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 11.61% mean?
Kintor Pharmaceutical (KNTPF) has a Net Debt Paydown Yield % of 11.61% as of Jul. 08, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Kintor Pharmaceutical and its competitors. According to the industry distribution chart, Kintor Pharmaceutical ranks #87 out of 1157 companies in the Biotechnology industry, placing it in the top 7.5%.
Is Kintor Pharmaceutical's Net Debt Paydown Yield % too high?
Kintor Pharmaceutical's current Net Debt Paydown Yield % is 11.61%. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Kintor Pharmaceutical's value of 11.61% is 38600% above this industry median. Based on the distribution chart, Kintor Pharmaceutical ranks #87 out of 1157 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kintor Pharmaceutical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Net Debt Paydown Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #87 out of 1157 companies for Net Debt Paydown Yield %. This places Kintor Pharmaceutical in the top 8% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. Kintor Pharmaceutical's value of 11.61% is 38600% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kintor Pharmaceutical's current Net Debt Paydown Yield % of 11.61% is 38600% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Kintor Pharmaceutical and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current Net Debt Paydown Yield % is 11.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Net Debt Paydown Yield % of 11.61%. The current Net Debt Paydown Yield % is 11.61% and 38600% above the Biotechnology industry median of 0.03. Kintor Pharmaceutical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Net Debt Paydown Yield % is 11.61% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
26GF Score
Get the complete analysis for KNTPF
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
